CoChat
Sign Up
Cited by 82Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline

Open access
Boccalini, Cecilia, Ribaldi, Federica, Hristovska, Ines, Arnone, Annachiara, Peretti, Débora Elisa, Mu, Linjing, Scheffler, Max, Perani, Daniela +2 more·2024·Alzheimer's & Dementia
DOI 10.1002/alz.13355PMC PMC10916991
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Tau and neurodegeneration strongly correlate with cognitive impairment, as compared to amyloid. However, their contribution in explaining cognition and predicting cognitive decline in memory clinics remains unclarified. METHODS: We included 94 participants with Mini‐Mental State Examination (MMSE), tau positron emission tomography (PET), amyloid PET, fluorodeoxyglucose (FDG) PET, and MRI scans from Geneva Memory Center. Linear regression and mediation analyses tested the independent and combined association between biomarkers, cognitive performance, and decline. Linear mixed‐effects and Cox proportional hazards models assessed biomarkers’ prognostic values. RESULTS: Metabolism had the strongest association with cognition (r = 0.712; p < 0.001), followed by tau (r = ‐0.682; p < 0.001). Neocortical tau showed the strongest association with cognitive decline (r = ‐0.677; p < 0.001). Metabolism mediated the association between tau and cognition and marginally mediated the one with decline. Tau positivity represented the strongest risk factor for decline (hazard ratio = 32). DISCUSSION: Tau and neurodegeneration synergistically contribute to global cognitive impairment while tau drives decline. The tau PET superior prognostic value supports its implementation in memory clinics. Highlights: Hypometabolism has the strongest association with concurrent cognitive impairment. Neocortical tau pathology is the main determinant of cognitive decline over time. FDG‐PET has a superior value compared to MRI as a measure of neurodegeneration. The prognostic value of tau‐PET exceeded all other neuroimaging modalities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.13355

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intracellular aggregates of hyperphosphorylated Tau correlate with cognitive decline in Alzheimer's disease.

    “One of the pathological hallmarks of Alzheimer’s disease is the intracellular aggregates of hyperphosphorylated Tau, which show good correlation to cognitive decline [1, 2].”

    From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [2]

    The Background identifies neurofibrillary tangles as the tau biomarker, and the Discussion reports that neocortical tau predicted longitudinal cognitive decline. However, the paper assesses tau deposition with PET; our copy does not directly establish that the intracellular aggregates of hyperphosphorylated tau, specifically, were what correlated with decline. The indexed passages have no page numbers. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 70 · Cited by 82

Research works printed but not linked: 62

  1. [3]Bilgel M, Wong DF, Moghekar AR, Ferrucci L, Resnick SM. Causal links among amyloid, tau, and neurodegeneration. Brain Commun. 2022; 4(4): 1‐ 13. doi: 10.1093/braincomms/fcac193 PMC9345312 35938073 · DOI
  2. [4]Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016; 139(5): 1551‐ 1567. doi: 10.1093/brain/aww027 26962052 PMC5006248 · DOI · Paper page
  3. [5]Tanner JA, Iaccarino L, Edwards L, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late‐onset Alzheimer's disease. Brain. 2022: awac229. doi: 10.1093/brain/awac229. Published online. PMC10200306 35762829 · DOI
  4. [6]Bejanin A, Schonhaut DR, La Joie R, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017; 140(12): 3286‐ 3300. doi: 10.1093/brain/awx243 29053874 PMC5841139 · DOI · Paper page
  5. [7]Whitwell JL, Graff‐Radford J, Tosakulwong N, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's Dement. 2018; 14(8): 1005‐ 1014. 29605222 PMC6097955
  6. [8]Ossenkoppele R, Zwan MD, Tolboom N, et al. Amyloid burden and metabolic function in early‐onset Alzheimer's disease: parietal lobe involvement. Brain. 2012; 135(7): 2115‐ 2125. doi: 10.1093/brain/aws113 22556189 · DOI · Paper page
  7. [9]Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early‐onset Alzheimer's disease is not related to amyloid burden. Brain. 2010; 133(2): 512‐ 528. doi: 10.1093/brain/awp326 20080878 PMC2858015 · DOI
  8. [10]Iaccarino L, Edwards L, et al. Spatial relationships between molecular pathology and neurodegeneration in the Alzheimer's disease continuum. Cereb Cortex. 2021; 31(1): 1‐ 14. doi: 10.1093/cercor/bhaa184 32808011 PMC7727356 · DOI
  9. [11]Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner M, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA ‐ J Am Med Assoc. 2017; 317(22): 2305‐ 2316. doi: 10.1001/jama.2017.6669 PMC5736301 28609533 · DOI · Paper page
  10. [13]Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology. Biol Psychiatry. 2021; 89(8): 786‐ 794. doi: 10.1016/j.biopsych.2020.06.029 32919611 PMC9682985 · DOI
  11. [14]Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015; 138(10): 2814‐ 2833. doi: 10.1093/brain/awv236 26283673 · DOI · Paper page
  12. [15]Hammond TC, Xing X, Wang C, et al. β‐amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. Commun Biol. 2020; 3(1): 1‐ 13. doi: 10.1038/s42003-020-1079-x 32632135 PMC7338410 · DOI
  13. [17]Chételat G, Arbizu J, Barthel H, et al. Amyloid‐PET and 18F‐FDG‐PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurol. 2020; 19(11): 951‐ 962. doi: 10.1016/S1474-4422(20)30314-8 33098804 · DOI · Paper page
  14. [19]Tosun D, Demir Z, Veitch DP, et al. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's Dement. 2021: 1‐ 13. doi: 10.1002/alz.12480. August. PMC9014819 34647694 · DOI
  15. [20]Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019; 76(8): 915‐ 924. doi: 10.1001/jamaneurol.2019.1424 31157827 PMC6547132 · DOI · Paper page
  16. [22]Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET‐positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022: 1‐ 7. Published online. 36357681 PMC9671808
  17. [23]Strikwerda‐Brown C, Hobbs D, Gonneaud J, et al. Association of elevated amyloid and tau positron emission tomography signal with near‐term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2023; 79(10): 975‐ 985. doi: 10.1001/jamaneurol.2022.2379 PMC9339146 35907254 · DOI
  18. [24]Ribaldi F, Chicherio C, Altomare D, et al. Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimer's Res Ther. 2021; 13(1): 1‐ 8. doi: 10.1186/s13195-021-00846-z 34034799 PMC8152092 · DOI
  19. [25]Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011; 7(3): 270‐ 279. 21514249 PMC3312027
  20. [26]Jefferies E, Thompson H, Cornelissen P, Smallwood J. The neurocognitive basis of knowledge about object identity and events: dissociations reflect opposing effects of semantic coherence and control. Philos Trans R Soc B Biol Sci. 2020; 375(1791): 20190300. doi: 10.1098/rstb.2019.0300 PMC6939353 31840592 · DOI
  21. [27]Shcherbinin S, Schwarz AJ, Joshi A, et al. Kinetics of the tau PET tracer 18F‐AV‐1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med. 2016; 57(10): 1535‐ 1542. doi: 10.2967/jnumed.115.170027. Published online 2016. 27151986 · DOI
  22. [28]Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2021(0123456789). doi: 10.1007/s00259-021-05603-w PMC8803744 34882261 · DOI
  23. [29]Boellaard R, Delgado‐Bolton R, Oyen WJG, et al. FDG PET/CT: eANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2): 328‐ 354. doi: 10.1007/s00259-014-2961-x 25452219 PMC4315529 · DOI · Paper page
  24. [30]Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. Neuroimage. 2020; 206: 116189. doi: 10.1016/j.neuroimage.2019.116189. August 2019. 31521825 · DOI
  25. [31]Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer's Dement. 2015; 11(1): 1‐ 15. 25443857 PMC4300247
  26. [32]Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's Dement. 2017; 13(3): 205‐ 216. doi: 10.1016/j.jalz.2016.08.005 27697430 PMC5344738 · DOI · Paper page
  27. [34]Mishra S, Gordon BA, Su Y, et al. AV‐1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage. 2017; 161(July): 171‐ 178. doi: 10.1016/j.neuroimage.2017.07.050 28756238 PMC5696044 · DOI
  28. [35]Dodich A, Mendes A, Assal F, et al. The A/T/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging. 2020; 47(2): 247‐ 255. doi: 10.1007/s00259-019-04536-9 31792573 · DOI
  29. [36]Perani D, Della Rosa PA, Cerami C, et al. Validation of an optimized SPM procedure for FDG‐PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 2014; 6: 445‐ 454. doi: 10.1016/j.nicl.2014.10.009 25389519 PMC4225527 · DOI
  30. [37]Cerami C, Della Rosa PA, Magnani G, et al. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. NeuroImage Clin. 2015; 7: 187‐ 194. doi: 10.1016/j.nicl.2014.12.004 25610780 PMC4300010 · DOI · Paper page
  31. [38]Teune LK, Bartels AL, De Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010; 25(14): 2395‐ 2404. doi: 10.1002/mds.23291 20669302 · DOI
  32. [39]Morbelli S, Bauckneht M, Arnaldi D, et al. 18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging. 2017; 44(12): 2073‐ 2083. doi: 10.1007/s00259-017-3790-5 28785843 · DOI
  33. [40]Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG‐PET measures of decline in AD and MCI. Neurobiol Aging. 2011; 32(7): 1207‐ 1218. doi: 10.1016/j.neurobiolaging.2009.07.002 19660834 PMC2891865 · DOI · Paper page
  34. [41]FreeSurfe Fischl. Neuroimage. 2012; 62(2): 774‐ 781. 22248573 PMC3685476
  35. [42]Mattsson‐Carlgren N, Leuzy A, Janelidze S, et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology. 2020; 94(21): e2233‐ e2244. doi: 10.1212/WNL.0000000000009485 Published online 2020 32398359 PMC7357296 · DOI · Paper page
  36. [43]Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007; 38(1): 95‐ 113. 17761438
  37. [44]Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015; 84(11): 1121‐ 1127. doi: 10.1212/WNL.0000000000001376 25681452 PMC4371405 · DOI
  38. [45]Xia M, Wang J, He Y. BrainNet Viewer: a network visualization tool for human brain connectomics. PLoS One. 2013; 8(7): e68910. 23861951 PMC3701683
  39. [46]Chételat G. Alzheimer disease: aβ‐independent processes‐rethinking preclinical AD. Nat Rev Neurol. 2013; 9(3): 123‐ 124. doi: 10.1038/nrneurol.2013.21 23399647 PMC3935395 · DOI · Paper page
  40. [47]Frisoni GB, Altomare D, Thal DR, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022; 23(1): 53‐ 66. doi: 10.1038/s41583-021-00533-w 34815562 PMC8840505 · DOI · Paper page
  41. [48]Hampel H, Cummings J, Blennow K, Gao P, Jack CR, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021; 17(9): 580‐ 589. doi: 10.1038/s41582-021-00520-w 34239130 · DOI
  42. [49]Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: delphi consensus. Eur J Neurol. 2018; 25(10): 1201‐ 1217. 29932266
  43. [50]Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022; 63(6): 20S‐ 26S. doi: 10.2967/jnumed.121.263196 35649647 · DOI · Paper page
  44. [51]Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1991; 30(4): 572‐ 580. 1789684
  45. [52]Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2): 207‐ 216. doi: 10.1016/S1474-4422(12)70291-0 23332364 PMC3622225 · DOI · Paper page
  46. [53]Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012; 72(4): 578‐ 586. doi: 10.1002/ana.23650 23109153 PMC3786871 · DOI
  47. [54]Strom A, Iaccarino L, Edwards L, et al. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Brain. 2022; 145(2): 713‐ 728. doi: 10.1093/brain/awab294 34373896 PMC9014741 · DOI · Paper page
  48. [55]Villemagne VL, Lopresti BJ, Doré V, et al. What is T+? A gordian knot of tracers, thresholds, and topographies. J Nucl Med. 2021; 62(5): 614‐ 619. doi: 10.2967/jnumed.120.245423 33384320 · DOI
  49. [56]Sala A, Caprioglio C, Santangelo R, et al. Brain metabolic signatures across the Alzheimer's disease spectrum. Eur J Nucl Med Mol Imaging. 2019. 31811345
  50. [57]Saint‐Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A. Regional tau deposition measured by [ 18 F] THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer ’ s disease. Alzheimers Res Ther. 2016: 1‐ 9. doi: 10.1186/s13195-016-0204-z. Published online. 27683159 PMC5041516 · DOI
  51. [59]Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019; 92(6): e601‐ e612. doi: 10.1212/WNL.0000000000006875 30626656 PMC6382060 · DOI
  52. [60]Ossenkoppele R, Iaccarino L, Schonhaut DR, et al. Tau covariance patterns in Alzheimer ’ s disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage Clin. 2019; 23: 101848. doi: 10.1016/j.nicl.2019.101848. September 2018. 31077982 PMC6510968 · DOI
  53. [61]Chételat G, Desgranges B, Landeau B, et al. Direct voxel‐based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain. 2008; 131(1): 60‐ 71. doi: 10.1093/brain/awm288 18063588 · DOI
  54. [62]Ossenkoppele R, Smith R, Mattsson‐Carlgren N, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal alzheimer disease: a head‐to‐head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021; 78(6): 961‐ 971. doi: 10.1001/jamaneurol.2021.1858. Published online 2021. 34180956 PMC8240013 · DOI · Paper page
  55. [63]Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE): consensus working group report. Brain. 2019; 142(6): 1503‐ 1527. 31039256 PMC6536849
  56. [64]Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood‐based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022; 21(1): 66‐ 77. doi: 10.1016/S1474-4422(21)00361-6 34838239 · DOI · Paper page
  57. [65]Smith R, Cullen NC, Pichet Binette A, et al. Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients. Alzheimer's Dement. 2022: 1‐ 11. doi: 10.1002/alz.12875. October. PMC10264552 36516028 · DOI · Paper page
  58. [66]Leuzy A, Smith R, Cullen NC, et al. Biomarker‐based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 2022; 79(2): 149‐ 158. doi: 10.1001/jamaneurol.2021.4654 34928318 PMC8689441 · DOI · Paper page
  59. [67]Groot C, Smith R, Stomrud E, et al. Phospho‐tau with subthreshold tau‐PET predicts increased tau accumulation rates in amyloid‐positive individuals. Brain. 2022; 146(4): 1580‐ 1591. Published online. PMC10115173 36084009
  60. [68]Altomare D, Stampacchia S, Ribaldi F, et al. Plasma biomarkers for Alzheimer's disease: a field‐test in a memory clinic. Submitted. 2022: 1‐ 8. doi: 10.1136/jnnp-2022-330619. Published online. PMC10314086 37012066 · DOI
  61. [69]Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimer's Dement. 2013; 9(5): 529‐ 537. doi: 10.1016/j.jalz.2012.10.001 23260866 PMC4036230 · DOI
  62. [70]Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimer's Dement. 2017; 13(9): 1004‐ 1012. 28253478 PMC5573651

Authors
Boccalini, C., Ribaldi, F., Hristovska, I., Arnone, A., Peretti, D. E., Mu, L., Scheffler, M., Perani, D., Frisoni, G. B., & Garibotto, V.
Affiliations
  • University of Geneva (CH)
  • Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine University of Geneva Geneva Switzerland
  • ETH Zurich (CH)
  • University Hospital of Geneva (CH)
  • Vita-Salute San Raffaele University (IT)
Corresponding author
Garibotto, Valentina
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2023-08-09
Volume
20
Issue
1
Pages
221-233
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.13355
PMC
PMC10916991
OpenAlex
W4385684558
Cited by
82
References
70
Citations by year
2026: 22 · 2025: 33 · 2024: 23 · 2023: 4
FWCI
16.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by-nc)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc)
  • ETH Zürich Research Collection
Funders
  • National Science Foundation
  • European Commission (115736)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (169876, 115952, 182772)
  • Hôpitaux Universitaires de Genève
  • Fondation Segré
  • Horizon 2020 Framework Programme (667375, 115952)
  • Avid Radiopharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
tau PET, hypometabolism
MeSH terms
Alzheimer Disease, Amyloid, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Fluorodeoxyglucose F18, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review